$VRNA
Verona Pharma PLC Stock $vrna

$vrna Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000165731224000025 Filed on August 08, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q4
Revenue	$5.624M	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue	$543.0K		$0.00
YoY Change			-100.0%
Gross Profit	$5.081M		$0.00
YoY Change			-100.0%
Gross Profit Margin	90.34%
Selling, General & Admin	$35.20M	$49.04M	$14.97M
YoY Change	163.58%	294.17%	79.89%
% of Gross Profit	692.7%
Research & Development	$10.55M	$19.39M	$4.122M
YoY Change	256.73%	1631.07%	-39.72%
% of Gross Profit	207.68%
Depreciation & Amortization	$266.0K	$270.0K	$208.0K
YoY Change	71.61%	71.97%	37.75%
% of Gross Profit	5.24%
Operating Expenses	$46.29M	$68.42M	$19.09M
YoY Change	183.8%	586.63%	25.94%
Operating Profit	-$40.67M	-$68.42M	-$19.09M
YoY Change	149.32%	586.63%	26.88%
Interest Expense	$9.882M	$1.757M	$3.875M
YoY Change	2364.34%	137.43%	-16.58%
% of Operating Profit
Other Income/Expense, Net	-$2.045M	-$1.398M	$1.034M
YoY Change	-222.6%	-195.23%	29.9%
Pretax Income	-$42.71M	-$69.82M	-$14.19M
YoY Change	191.69%	721.71%	36.09%
Income Tax	$250.0K	$1.014M	-$53.00K
% Of Pretax Income
Net Earnings	-$42.96M	-$70.84M	-$14.13M
YoY Change	192.52%	704.3%	35.22%
Net Earnings / Revenue	-763.9%
Basic Earnings Per Share	-$0.07	-$0.11
Diluted Earnings Per Share	-$0.07	-$0.11	-$0.02
COMMON SHARES
Basic Shares Outstanding	649.9M shares	648.7M shares	639.5M shares
Diluted Shares Outstanding	651.9M shares	648.2M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$336.0M	$404.6M	$271.8M
YoY Change	30.57%	49.45%	19.29%
Cash & Equivalents	$336.0M	$404.6M	$271.8M
Short-Term Investments
Other Short-Term Assets	$3.443M	$2.576M	$3.365M
YoY Change	-45.51%	-57.49%	-0.68%
Inventory	$4.315M		$0.00
Prepaid Expenses	$7.964M	$5.433M	$3.617M
Receivables	$6.904M		$0.00
Other Receivables	$5.587M
Total Short-Term Assets	$364.3M	$416.3M	$289.7M
YoY Change	31.72%	44.63%	19.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$40.00K	$44.00K	$24.00K
YoY Change	300.0%	300.0%	-67.12%
Goodwill	$545.0K	$545.0K	$545.0K
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$15.00M	$15.00M	$15.00M
YoY Change	0.0%	0.0%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$17.57M	$17.83M	$18.42M
YoY Change	10.17%	10.77%	11.8%
TOTAL ASSETS
Total Short-Term Assets	$364.3M	$416.3M	$289.7M
Total Long-Term Assets	$17.57M	$17.83M	$18.42M
Total Assets	$381.8M	$434.1M	$308.1M
YoY Change	30.55%	42.84%	18.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.831M	$4.152M	$3.492M
YoY Change	730.01%	66.55%	20.0%
Accrued Expenses	$18.14M	$19.63M	$3.585M
YoY Change	145.28%	162.89%	-73.93%
Deferred Revenue	$169.0K	$21.32M	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$27.95M	$48.35M	$8.692M
YoY Change	210.14%	341.56%	-54.32%
LONG-TERM LIABILITIES
Long-Term Debt	$120.0M	$119.7M	$48.37M
YoY Change	502.91%	502.74%	395.23%
Other Long-Term Liabilities	$103.4M	$97.82M	$1.775M
YoY Change	516740.0%	325953.33%	765.85%
Total Long-Term Liabilities	$223.4M	$217.5M	$50.15M
YoY Change	1021.09%	993.69%	402.85%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.95M	$48.35M	$8.692M
Total Long-Term Liabilities	$223.4M	$217.5M	$50.15M
Total Liabilities	$251.3M	$265.8M	$58.84M
YoY Change	768.53%	762.14%	102.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$528.5M	-$485.3M	-$388.4M
YoY Change	41.27%	35.14%	16.6%
Common Stock	$42.77M	$42.77M	$42.77M
YoY Change	2.44%	2.44%	5.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$828.0K	$1.203M	$1.517M
YoY Change	10.99%	23.38%	-2.07%
Treasury Stock Shares
Shareholders Equity	$130.5M	$168.3M	$249.3M
YoY Change
Total Liabilities & Shareholders Equity	$381.8M	$434.1M	$308.1M
YoY Change	30.55%	42.84%	18.75%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q4
OPERATING ACTIVITIES
Net Income	-$42.96M	-$70.84M	-$14.13M
YoY Change	192.52%	704.3%	35.22%
Depreciation, Depletion And Amortization	$266.0K	$270.0K	$208.0K
YoY Change	71.61%	71.97%	37.75%
Cash From Operating Activities	-$62.66M	-$17.10M	-$10.40M
YoY Change	392.3%	-19.75%	34.43%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$29.00K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$29.00K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-7.087M	166.8M	24.01M
YoY Change	-14864.58%	134441.94%	818.59%
NET CHANGE
Cash From Operating Activities	-62.66M	-17.10M	-10.40M
Cash From Investing Activities	0.000	-29.00K	0.000
Cash From Financing Activities	-7.087M	166.8M	24.01M
Net Change In Cash	-69.74M	149.7M	13.61M
YoY Change	450.06%	-806.57%	-365.61%
FREE CASH FLOW
Cash From Operating Activities	-$62.66M	-$17.10M	-$10.40M
Capital Expenditures	$0.00	$29.00K	$0.00
Free Cash Flow	-$62.66M	-$17.13M	-$10.40M
YoY Change	392.3%	-19.61%	34.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5433000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3617000	usd
CY2024Q2	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	3684000	usd
CY2023Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	10954000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	545000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	545000	usd
CY2024Q2	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4152000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3492000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19630000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3585000	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2576000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3365000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	416292000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	289708000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2242000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2847000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5074000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19852000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-70835000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	648217000	shares
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	57500000	shares
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3653000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2024Q2	us-gaap	Investment Income Net InvestmentIncomeNet	3140000	usd
CY2023Q2	us-gaap	Investment Income Net InvestmentIncomeNet	3402000	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	17831000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	18416000	usd
CY2024Q2	us-gaap	Assets Assets	434123000	usd
CY2023Q4	us-gaap	Assets Assets	308124000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	21322000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1031000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1180000	usd
CY2024Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	1011000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1200000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	435000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	48346000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8692000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	119687000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	48374000	usd
CY2024Q2	vrna	Securites Purchased Noncurrent Revenue Interest SecuritesPurchasedNoncurrentRevenueInterest	96338000	usd
CY2023Q4	vrna	Securites Purchased Noncurrent Revenue Interest SecuritesPurchasedNoncurrentRevenueInterest	0	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1478000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1775000	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	217503000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	50149000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	265849000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	58841000	usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	667659630	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	667659630	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	648654174	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	643536094	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	42771000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	42771000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	616618000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	601063000	usd
CY2024Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1203000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1517000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-485311000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-388433000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	168274000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	249283000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	434123000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	308124000	usd
CY2024Q2	vrna	Research And Development Expense Net Of Adjustments ResearchAndDevelopmentExpenseNetOfAdjustments	19388000	usd
CY2023Q2	vrna	Research And Development Expense Net Of Adjustments ResearchAndDevelopmentExpenseNetOfAdjustments	-2474000	usd
	vrna	Research And Development Expense Net Of Adjustments ResearchAndDevelopmentExpenseNetOfAdjustments	26152000	usd
	vrna	Research And Development Expense Net Of Adjustments ResearchAndDevelopmentExpenseNetOfAdjustments	10136000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	49035000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12439000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	69469000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22028000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	68423000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	9965000	usd
	us-gaap	Operating Expenses OperatingExpenses	95621000	usd
	us-gaap	Operating Expenses OperatingExpenses	32164000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-68423000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9965000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-95621000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-32164000	usd
CY2024Q2	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	847000	usd
CY2023Q2	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	-1934000	usd
	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	1432000	usd
	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	379000	usd
CY2024Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3653000	usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	6518000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	6079000	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	1757000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	740000	usd
	us-gaap	Interest Expense InterestExpense	3343000	usd
	us-gaap	Interest Expense InterestExpense	1033000	usd
CY2024Q2	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	25000	usd
CY2023Q2	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	740000	usd
	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	-194000	usd
	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	1672000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1398000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1468000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	760000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7097000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-69821000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8497000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-94861000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25067000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1014000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	310000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1768000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	483000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-70835000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8807000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-96629000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25550000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	648217000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	648217000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	634469000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	634469000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	646959000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	646959000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	627996000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	627996000	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	249283000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-25794000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	816000	usd
CY2024Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3338000	usd
CY2024Q1	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	237000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4258000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	224988000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-70835000	usd
CY2024Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1273000	usd
CY2024Q2	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	200000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15594000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	168274000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	230466000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-16743000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1827000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4290000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	276749000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8807000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	77000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5074000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	273093000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-96629000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25550000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-194000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1672000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	285000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	88000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	120000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	51000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3653000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	19852000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9364000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	533000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	314000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1816000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1605000	usd
	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	-7201000	usd
	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	380000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-35000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2016000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	756000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-417000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	11617000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6285000	usd
	vrna	Increase Decrease In License Agreement Obligations IncreaseDecreaseInLicenseAgreementObligations	21322000	usd
	vrna	Increase Decrease In License Agreement Obligations IncreaseDecreaseInLicenseAgreementObligations	0	usd
	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-365000	usd
	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-305000	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	1765000	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-939000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	765000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-951000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30712000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27093000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-45000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56909000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	122500000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	9996000	usd
	vrna	Proceeds From Revenue Interest Purchase And Sale Agreement Ripsa ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA	100000000	usd
	vrna	Proceeds From Revenue Interest Purchase And Sale Agreement Ripsa ProceedsFromRevenueInterestPurchaseAndSaleAgreementRIPSA	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2303000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	52256000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5048000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	816000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1904000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	163709000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	68809000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-125000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1184000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	132827000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	42900000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	271772000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	227827000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	404599000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	270727000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1215000	usd
	us-gaap	Interest Paid Net InterestPaidNet	2021000	usd
	us-gaap	Interest Paid Net InterestPaidNet	685000	usd
	vrna	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	1	subsidiary
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-485300000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known, and actual results could differ from the Company’s estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Inventories, including Pre-Launch Inventories</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Prior to obtaining regulatory approval for Ohtuvayre, the Company expensed costs relating to production of pre-launch inventory as research and development expense in its condensed consolidated statements of operations and comprehensive loss in the period incurred. Inventory acquired and the related costs after June 26, 2024, the date of the FDA’s approval of Ohtuvayre, will be capitalized. Products used in clinical trials are expensed as research and development expense in the statement of operations and comprehensive loss. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company will value its inventories at the lower-of-actual cost or net realizable value. Due to the timing of the approval of Ohtuvayre, the Company did not capitalize any inventory costs in the three or six months ended June 30, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Revenue Interest Purchase and Sale Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The revenue interest purchase and sale agreement (the “RIPSA”) liability is eligible to be repaid based on royalties from net sales of Ohtuvayre (ensifentrine) and any other future products. Interest expense is accrued using the effective interest rate method over the estimated period the related liability will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of the RIPSA and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">that the Company make estimates that could impact the carrying value of the liability, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Recently issued accounting standards not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The amendments in this ASU are effective for annual periods beginning on December 15, 2024, and should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its income tax disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity's overall performance and assess potential future cash flows. The amendments in this ASU are effective for annual periods beginning on December 15, 2023 and interim periods beginning on December 15, 2024 and should be applied on a retrospective basis for all periods presented. This ASU will have no impact on the Company's Consolidated Balance Sheets or Consolidated Statements of Operations and Comprehensive Loss. The Company is currently evaluating the impact to its segment disclosures.</span></div>
CY2024Q2	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	5959000	usd
CY2023Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	752000	usd
CY2024Q2	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	5095000	usd
CY2023Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	2039000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3964000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	794000	usd
CY2024Q2	vrna	Accrued Debt Issuance Costs Current AccruedDebtIssuanceCostsCurrent	4612000	usd
CY2023Q4	vrna	Accrued Debt Issuance Costs Current AccruedDebtIssuanceCostsCurrent	0	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19630000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3585000	usd
CY2024Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.20
CY2024Q2	vrna	Accrued Debt Issuance Costs Current AccruedDebtIssuanceCostsCurrent	4600000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15594000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9364000	usd
CY2024Q2	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	24689624	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2432000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	64000	shares
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1037424	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	26020200	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7924000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	72000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	160000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	33712200	shares
CY2024Q2	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8807000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-96629000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25550000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	648217000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	634469000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	634469000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	646959000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	646959000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	627996000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	627996000	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	57500000	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	48500000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	48500000	shares
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001657312-24-000025-index-headers.html	Edgar Link	pending
0001657312-24-000025-index.html	Edgar Link	pending
0001657312-24-000025.txt	Edgar Link	pending
0001657312-24-000025-xbrl.zip	Edgar Link	pending
exhibit311q224.htm	Edgar Link	pending
exhibit312q224.htm	Edgar Link	pending
exhibit321q224.htm	Edgar Link	pending
exhibit322q224.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
redactedverona-revenuein.htm	Edgar Link	pending
redactedverona-revenuein001.jpg	Edgar Link	pending
redactedverona-revenuein002.jpg	Edgar Link	pending
redactedverona-revenuein003.jpg	Edgar Link	pending
redactedverona-revenuein004.jpg	Edgar Link	pending
redactedverona-revenuein005.jpg	Edgar Link	pending
redactedverona-revenuein006.jpg	Edgar Link	pending
redactedverona-revenuein007.jpg	Edgar Link	pending
redactedverona-revenuein008.jpg	Edgar Link	pending
redactedverona-revenuein009.jpg	Edgar Link	pending
redactedverona-revenuein010.jpg	Edgar Link	pending
redactedverona-revenuein011.jpg	Edgar Link	pending
redactedverona-revenuein012.jpg	Edgar Link	pending
redactedverona-revenuein013.jpg	Edgar Link	pending
redactedverona-revenuein014.jpg	Edgar Link	pending
redactedverona-revenuein015.jpg	Edgar Link	pending
redactedverona-revenuein016.jpg	Edgar Link	pending
redactedverona-revenuein017.jpg	Edgar Link	pending
redactedverona-revenuein018.jpg	Edgar Link	pending
redactedverona-revenuein019.jpg	Edgar Link	pending
redactedverona-revenuein020.jpg	Edgar Link	pending
redactedverona-revenuein021.jpg	Edgar Link	pending
redactedverona-revenuein022.jpg	Edgar Link	pending
redactedverona-revenuein023.jpg	Edgar Link	pending
redactedverona-revenuein024.jpg	Edgar Link	pending
redactedverona-revenuein025.jpg	Edgar Link	pending
redactedverona-revenuein026.jpg	Edgar Link	pending
redactedverona-revenuein027.jpg	Edgar Link	pending
redactedverona-revenuein028.jpg	Edgar Link	pending
redactedverona-revenuein029.jpg	Edgar Link	pending
redactedverona-revenuein030.jpg	Edgar Link	pending
redactedverona-revenuein031.jpg	Edgar Link	pending
redactedverona-revenuein032.jpg	Edgar Link	pending
redactedverona-revenuein033.jpg	Edgar Link	pending
redactedverona-revenuein034.jpg	Edgar Link	pending
redactedverona-revenuein035.jpg	Edgar Link	pending
redactedverona-revenuein036.jpg	Edgar Link	pending
redactedverona-revenuein037.jpg	Edgar Link	pending
redactedverona-revenuein038.jpg	Edgar Link	pending
redactedverona-revenuein039.jpg	Edgar Link	pending
redactedverona-revenuein040.jpg	Edgar Link	pending
redactedverona-revenuein041.jpg	Edgar Link	pending
redactedverona-revenuein042.jpg	Edgar Link	pending
redactedverona-revenuein043.jpg	Edgar Link	pending
redactedverona-revenuein044.jpg	Edgar Link	pending
redactedverona-revenuein045.jpg	Edgar Link	pending
redactedverona-revenuein046.jpg	Edgar Link	pending
redactedverona-revenuein047.jpg	Edgar Link	pending
redactedverona-revenuein048.jpg	Edgar Link	pending
redactedverona-revenuein049.jpg	Edgar Link	pending
redactedverona-revenuein050.jpg	Edgar Link	pending
redactedverona-revenuein051.jpg	Edgar Link	pending
redactedverona-revenuein052.jpg	Edgar Link	pending
redactedverona-revenuein053.jpg	Edgar Link	pending
redactedverona-revenuein054.jpg	Edgar Link	pending
redactedverona-revenuein055.jpg	Edgar Link	pending
redactedverona-revenuein056.jpg	Edgar Link	pending
redactedverona-revenuein057.jpg	Edgar Link	pending
redactedverona-revenuein058.jpg	Edgar Link	pending
redactedverona-revenuein059.jpg	Edgar Link	pending
redactedverona-revenuein060.jpg	Edgar Link	pending
redactedverona-revenuein061.jpg	Edgar Link	pending
redactedverona-revenuein062.jpg	Edgar Link	pending
redactedverona-revenuein063.jpg	Edgar Link	pending
redactedverona-revenuein064.jpg	Edgar Link	pending
redactedverona-revenuein065.jpg	Edgar Link	pending
redactedverona-revenuein066.jpg	Edgar Link	pending
redactedverona-revenuein067.jpg	Edgar Link	pending
redactedverona-revenuein068.jpg	Edgar Link	pending
redactedverona-revenuein069.jpg	Edgar Link	pending
redactedverona-revenuein070.jpg	Edgar Link	pending
redactedverona-revenuein071.jpg	Edgar Link	pending
redactedverona-revenuein072.jpg	Edgar Link	pending
redactedverona-revenuein073.jpg	Edgar Link	pending
redactedverona-revenuein074.jpg	Edgar Link	pending
redactedverona-revenuein075.jpg	Edgar Link	pending
redactedverona-revenuein076.jpg	Edgar Link	pending
redactedverona-revenuein077.jpg	Edgar Link	pending
redactedverona-revenuein078.jpg	Edgar Link	pending
redactedverona-revenuein079.jpg	Edgar Link	pending
redactedverona-revenuein080.jpg	Edgar Link	pending
redactedverona-revenuein081.jpg	Edgar Link	pending
redactedverona-revenuein082.jpg	Edgar Link	pending
redactedverona-revenuein083.jpg	Edgar Link	pending
redactedverona-revenuein084.jpg	Edgar Link	pending
redactedverona-revenuein085.jpg	Edgar Link	pending
redactedverona-revenuein086.jpg	Edgar Link	pending
redactedverona-revenuein087.jpg	Edgar Link	pending
redactedverona-revenuein088.jpg	Edgar Link	pending
redactedverona-revenuein089.jpg	Edgar Link	pending
redactedverona-revenuein090.jpg	Edgar Link	pending
redactedverona-revenuein091.jpg	Edgar Link	pending
redactedverona-revenuein092.jpg	Edgar Link	pending
redactedverona-revenuein093.jpg	Edgar Link	pending
redactedverona-revenuein094.jpg	Edgar Link	pending
redactedverona-revenuein095.jpg	Edgar Link	pending
redactedverona-revenuein096.jpg	Edgar Link	pending
redactedverona-revenuein097.jpg	Edgar Link	pending
redactedverona-revenuein098.jpg	Edgar Link	pending
redactedverona-revenuein099.jpg	Edgar Link	pending
redactedverona-revenuein100.jpg	Edgar Link	pending
redactedverona-revenuein101.jpg	Edgar Link	pending
redactedverona-revenuein102.jpg	Edgar Link	pending
redactedverona-revenuein103.jpg	Edgar Link	pending
redactedverona-revenuein104.jpg	Edgar Link	pending
redactedverona-revenuein105.jpg	Edgar Link	pending
redactedverona-revenuein106.jpg	Edgar Link	pending
redactedverona-revenuein107.jpg	Edgar Link	pending
redactedverona-revenuein108.jpg	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vrna-20240630.htm	Edgar Link	pending
vrna-20240630.xsd	Edgar Link	pending
vrna-20240630_g1.jpg	Edgar Link	pending
vrna-20240630_cal.xml	Edgar Link	unprocessable
vrna-20240630_def.xml	Edgar Link	unprocessable
vrna-20240630_lab.xml	Edgar Link	unprocessable
vrna-20240630_pre.xml	Edgar Link	unprocessable
vrna-20240630_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRNA
Verona Pharma PLC Stock $vrna

2024 Q3 Form 10-Q Financial Statement

#000165731224000025 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA Verona Pharma PLC Stock $vrna

2024 Q3 Form 10-Q Financial Statement

#000165731224000025 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA
Verona Pharma PLC Stock $vrna